Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

A group of cystic fibrosis patients could be denied access to a cutting-edge therapy after manufacturer Vertex refused to submit data to cost-effectiveness body NICE. The manufacturer's decision ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...

Growing demand for its Cystic Fibrosis (CF) franchise continued to generate ... A pharmacist delivering a specific medication to a patient in a specialty pharmacy. Vertex Pharmaceuticals Incorporated ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

(RTTNews) - Vertex Pharmaceuticals (VRTX ... The expanded indication now includes cystic fibrosis patients aged 2 years and older with at least one non-class I mutation in the CFTR gene.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

Vertex Pharmaceuticals Incorporated ... for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...